

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 July 2022 (21.07.2022)



(10) International Publication Number
WO 2022/152290 A1

(51) International Patent Classification:

C07K 16/18 (2006.01) A61K 39/395 (2006.01)
C07K 16/46 (2006.01) G01N 33/577 (2006.01)
C12N 15/13 (2006.01) A61P 35/00 (2006.01)
C12N 15/63 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2022/072297

(22) International Filing Date:

17 January 2022 (17.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/072397

18 January 2021 (18.01.2021) CN

PCT/CN2021/142043

28 December 2021 (28.12.2021) CN

(71) Applicant: SUZHOU TRANSCENTA THERA-
PEUTICS CO., LTD. [CN/CN]; B6-501, 218 Xinghu
Street, Suzhou, Jiangsu 215123 (CN).

(72) Inventors: QIAN, Xueming; B6-501, 218 Xinghu Street,
Suzhou, Jiangsu 215123 (CN). CUI, Suli; B6-501,
218 Xinghu Street, Suzhou, Jiangsu 215123 (CN). LI,
Hongjun; B6-501, 218 Xinghu Street, Suzhou, Jiang-
su 215123 (CN). SUN, Di; B6-501, 218 Xinghu Street,
Suzhou, Jiangsu 215123 (CN). GUO, Huanhuan; B6-501,
218 Xinghu Street, Suzhou, Jiangsu 215123 (CN).

(74) Agent: JUN HE LAW OFFICES; 20/F, China Resources
Building 8 Jianguomenbei, Avenue, Beijing 100005 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: NOVEL ANTI-GREMLIN1 ANTIBODIES

(57) Abstract: The present disclosure provides herein anti-gremlin1 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

WO 2022/152290 A1